Similar Items: Characterizing population pharmacokinetic/pharmacodynamic relationships in pulmonary tuberculosis infected adults using nonlinear mixed effects modelling
- Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
- Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs
- The pharmacokinetics of lopinavir in HIV-infected adults receiving rifampicin with adjusted doses of lopinavir
- Population/ Nonlinear mixed-effects modelling of pharmacokinetics and pharmacodynamics of tuberculosis treatment
- Population pharmacokinetic modelling for dose optimization of esomeprazole to treat early-onset preeclampsia
- Population pharmacokinetic modelling to address the gaps in knowledge of commonly used HIV and TB drugs in children
Author: McIlleron, Helen
- Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs
- Optimization of 1st-line antituberculosis dosing regimens using a population pharmacokinetic approach: food effects, drug combinations and pharmacological effects
- Pharmacokinetic-Pharmacogenetic-and-Pharmacodynamic Adherence Relationships in Cohort South African HIV Infected Children on Lopinavir-and Nevirapine-Based Regimens
- Population pharmacokinetic models describing drug-drug interactions and variability in HIV infected South Africans on protease inhibitor-based antiretroviral regimens with and without tuberculosis
- Determinants and consequences of the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in a cohort of tuberculosis patients
- Variability in the pharmacokinetics of rifapentine in South African tuberculosis patients : a classical and population approach